Aragen Biologics Private Limited, a active private limited company, was established on 21 June 2023 in Uppal, Telangana, India. Engaging in drug formulation & development within the pharma sector, it holds CIN: U21001TS2023PTC174243. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹300.00 Cr and a paid-up capital of ₹286.94 Cr.
Its leadership includes Manmahesh Kantipudi (Non- Individual Subscriber), Robert Richard Ruffolo (Additional Director), Gunapati Reddy Venkat Keshav (Director). Past directors included Sachin Anand Dharap. It holds ₹140.00 Cr open charges and no settled loans. Its latest AGM occurred on 31 July 2025, with the balance sheet filed on 31 March 2025. It is based at Plot No. 28A, Ida Nacharam, Uppal, Telangana, 500076.
U21001TS2023PTC174243
174243
21 June 2023
₹300.00 Cr
₹286.94 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Aragen Biologics Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manmahesh Kantipudi | Non- Individual Subscriber | 21 Jun 2023 | Current |
| Robert Richard Ruffolo | Additional Director | 03 Jul 2025 | Current |
| Gunapati Reddy Venkat Keshav | Director | 21 Jun 2023 | Current |
| Subodh Shrinivas Deshmukh | Additional Director | 28 Oct 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Cfo | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Aragen Biologics Private Limited, for the financial year ended 2024, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
In 2024, Aragen Biologics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹1,400,000,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 May 2024 | Citi Bank N.A. | ₹20.00 Cr | Open |
| 30 May 2024 | Citi Bank N.A. | ₹120.00 Cr | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Aragen Biologics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Aragen Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aragen Biologics's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Subodh Shrinivas Deshmukh was appointed as a Additional Director was appointed as a Additional Director on 28 Oct 2025 & has been associated with this company since 1 month 3 days . was recorded as a recent event.
The activity Aragen Biologics Private Limited last Annual general meeting of members was held on 31 Jul 2025 as per latest MCA records. was completed.
Robert Richard Ruffolo was appointed as a Additional Director was appointed as a Additional Director on 03 Jul 2025 & has been associated with this company since 5 months . was recorded as a recent event.
Progress on Aragen Biologics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was documented.
Ramakrishna Kasturi was appointed as a Company Secretary was appointed as a Company Secretary on 29 Oct 2024 & has been associated with this company since 1 year 1 month . was recorded as a recent event.
Progress on Sachin Anand Dharap was appointed as a CFO was appointed as a CFO on 29 Oct 2024 & has been associated with this company since 1 year 1 month . was documented.
Hyderabad is getting a big boost in the pharma industry with Aragen Life Sciences investing Rs 2000 crore and creating 1500 jobs. This will make the city a top destination for drug discovery and development. CM Revanth Reddy's leadership is attracting big investments and showcasing our talent. Aragen's CEO is confident in Hyderabad's potential and plans to invest for the next 5 years..
The CIN of Aragen Biologics Private Limited is U21001TS2023PTC174243.
Aragen Biologics Private Limited is headquartered at Plot No. 28A, Ida Nacharam, Uppal, Telangana, 500076.
Aragen Biologics Private Limited was incorporated on 21 June 2023.
The current directors of Aragen Biologics Private Limited are
The primary industry of Aragen Biologics Private Limited is Pharma.
Aragen Biologics Private Limited is unlisted.
The authorized capital of Aragen Biologics Private Limited is ₹300.00 Cr, and the paid-up capital is ₹286.94 Cr.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX